A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. (Record no. 17777790)
[ view plain ]
000 -LEADER | |
---|---|
fixed length control field | 02346 a2200625 4500 |
005 - DATE AND TIME OF LATEST TRANSACTION | |
control field | 20250515110532.0 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
fixed length control field | 200804s 0 0 eng d |
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
International Standard Serial Number | 1569-8041 |
024 7# - OTHER STANDARD IDENTIFIER | |
Standard number or code | 10.1093/annonc/mdm607 |
Source of number or code | doi |
040 ## - CATALOGING SOURCE | |
Original cataloging agency | NLM |
Language of cataloging | eng |
Transcribing agency | NLM |
100 1# - MAIN ENTRY--PERSONAL NAME | |
Personal name | Tol, J |
264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
Date of production, publication, distribution, manufacture, or copyright notice | 20080416 |
245 00 - TITLE STATEMENT | |
Title | A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. |
Medium | [electronic resource] |
260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
Name of publisher, distributor, etc. | Annals of oncology : official journal of the European Society for Medical Oncology |
Date of publication, distribution, etc. | Apr 2008 |
300 ## - PHYSICAL DESCRIPTION | |
Extent | 734-8 p. |
Other physical details | digital |
500 ## - GENERAL NOTE | |
General note | Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Adult |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Aged |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Aged, 80 and over |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Antibodies, Monoclonal |
General subdivision | administration & dosage |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Antibodies, Monoclonal, Humanized |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Antineoplastic Combined Chemotherapy Protocols |
General subdivision | adverse effects |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Bevacizumab |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Capecitabine |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Carcinoma |
General subdivision | drug therapy |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Cetuximab |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Colorectal Neoplasms |
General subdivision | drug therapy |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Deoxycytidine |
General subdivision | administration & dosage |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Disease-Free Survival |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Drug Eruptions |
General subdivision | etiology |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Female |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Fluorouracil |
General subdivision | administration & dosage |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Humans |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Incidence |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Male |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Middle Aged |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Netherlands |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Organoplatinum Compounds |
General subdivision | administration & dosage |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Oxaliplatin |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Severity of Illness Index |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Survival Analysis |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Treatment Outcome |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Koopman, M |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Rodenburg, C J |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Cats, A |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Creemers, G J |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Schrama, J G |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Erdkamp, F L G |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Vos, A H |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Mol, L |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Antonini, N F |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Punt, C J A |
773 0# - HOST ITEM ENTRY | |
Title | Annals of oncology : official journal of the European Society for Medical Oncology |
Related parts | vol. 19 |
-- | no. 4 |
-- | p. 734-8 |
856 40 - ELECTRONIC LOCATION AND ACCESS | |
Uniform Resource Identifier | <a href="https://doi.org/10.1093/annonc/mdm607">https://doi.org/10.1093/annonc/mdm607</a> |
Public note | Available from publisher's website |
No items available.